Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 28.04 B
The data is delayed by 15 minutes.
ALXN is in the long-term up 2519% in 25 years.
Description: Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trials for its usage for the treatment of PNH pediatric trial, presensitized renal transplant, delayed kidney transplant graft function, hemolytic uremic syndrome, neuromyelitis optica, myasthenia gravis, and cold agglutinin disease. In addition, it develops Asfotase alfa that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; ALXN 1007, a novel humanized antibody for treating inflammatory disorders; and cPMP that is
|Shares Outstanding||224.02 M||EPS||3.07||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||17.14%||Sales Growth - Q/Q||0.14%||P/E||37.13|
|P/E To EPS Growth||P/S||12.36||P/BV||7.97||Price/Cash Per Share||14.56|
|Price/Free Cash Flow||55.69||ROA||13.34%||ROE||16.74%||ROI||15.36%|
|Current Ratio||4.92||Quick Ratio||4.61||Long Term Debt/Equity||0.05||Debt Ratio||0.17|
|Gross Margin||90.72%||Operating Margin||33.65%||Net Profit Margin||25.97%||Dividend Payout Ratio|
|Cash From Financing Activities||5.07 M||Cash From Investing Activities||-48.42 M||Cash From Operating Activities||23.03 M||Gross Profit||584.2 M|
|Net Profit||170.22 M||Operating Profit||181.08 M||Total Assets||13.17 B||Total Current Assets||2.53 B|
|Total Current Liabilities||769.17 M||Total Debt||3.5 B||Total Liabilities||4.61 B||Total Revenue||636.21 M|
|High 52 week||141.3||Low 52 week||93.94||Last close||130.9||Last change||-0.38%|
|RSI||41.11||Average true range||3.76||Beta||1.14||Volume||2.37 M|
|Simple moving average 20 days||-1.22%||Simple moving average 50 days||-2.32%||Simple moving average 200 days||5.77%|
|Performance Week||-0.6%||Performance Month||3.96%||Performance Quart||1.14%||Performance Half||10.45%|
|Performance Year||9.39%||Performance Year-to-date||34.45%||Volatility daily||1.92%||Volatility weekly||4.28%|
|Volatility monthly||8.78%||Volatility yearly||30.41%||Relative Volume||244.27%||Average Volume||1.33 M|
|New High||New Low|
2019-06-21 11:05:03 | Alexion's sBLA for Ultomiris Gets Priority Review From FDA
2019-06-21 10:01:02 | 3 Big Biotechs Hold Growth Potential in Second Half of 2019
2019-06-20 09:45:01 | The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara
2019-06-20 08:15:00 | U.S. FDA Accepts Supplemental Biologics License Application sBLA for ULTOMIRIS® ravulizumab-cwvz under Priority Review for the Treatment of Atypical Hemolytic Uremic Syndrome aHUS
2019-06-19 16:07:08 | Alexion's ALXN Ultomiris Gets Approval in Japan for PNH
2019-06-19 10:29:02 | Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data
2019-06-19 07:00:00 | Comet launches with $28M to turn Nobel Prize-winning science into drugs
2019-06-18 08:04:24 | See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
2019-06-18 06:30:00 | ULTOMIRIS® ravulizumab Receives Marketing Authorization from Japan’s Ministry of Health, Labour and Welfare MHLW for the Treatment of Adults with Paroxysmal Nocturnal Hemoglobinuria PNH
2019-06-17 18:17:10 | Alexion's ALXN PNH Drug Ultomiris Shows Long-Term Efficacy
2019-06-17 13:52:12 | Nasdaq Outperforms, Helped By Software, Biotech; Bitcoin Trading Heats Up
2019-06-14 14:18:37 | Is Alexion Pharmaceuticals, Inc.'s NASDAQ:ALXN High P/E Ratio A Problem For Investors?
2019-06-10 08:04:13 | See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
2019-06-07 13:22:08 | Here’s What Hedge Funds Think About Alexion Pharmaceuticals, Inc. ALXN
2019-06-07 05:19:00 | 7 Stocks Ripe for M&A as Trade War Pushes Market Off Record Highs
2019-06-06 08:45:12 | Is Alexion ALXN a Solid Growth Stock? 3 Reasons to Think " Yes "
2019-06-05 16:13:00 | 10 Stocks to Buy That Could Be Takeover Targets
2019-06-03 06:00:00 | Could this Biotech be the Best Summer Buy
2019-05-30 14:34:07 | Save the Date: 11 Biotech Stocks to Put on Your Radar
2019-05-29 12:34:22 | 2 Reasons to Like This Pharma Stock Right Now
2019-05-29 07:59:11 | 5 Best-Performing Summer Stocks to Add to Your Watch List
2019-05-26 09:00:00 | 3 Big Biotech Stocks That Warren Buffett Might Like
2019-05-25 09:31:01 | Why Is Alexion ALXN Down 6.3% Since Last Earnings Report?
2019-05-23 10:00:00 | 3 Top Biotech Stocks to Buy Right Now
2019-05-23 09:06:00 | Wedbush Securities Senior Vice President of Equity Research Laura Chico, Ph.D. Initiates Coverage on Six Stocks in the Healthcare and BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA and SAGE
2019-05-21 07:46:11 | Alexion ALXN Stock Up 30.7% YTD: Will the Momentum Stay?
2019-05-20 08:45:12 | 3 Reasons Growth Investors Will Love Alexion ALXN
2019-05-19 07:00:00 | Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big
2019-05-16 09:30:01 | ALXN or ALKS: Which Is the Better Value Stock Right Now?
2019-05-13 16:30:00 | Alexion to Present at the UBS Global Healthcare Conference
2019-05-13 16:30:00 | Alexion to Present at the RBC Capital Markets Annual Healthcare Conference
2019-05-13 09:13:01 | Achillion ACHN Reports Wider-Than-Expected Loss in Q1
2019-05-09 09:00:01 | What Makes Alexion ALXN a New Buy Stock
2019-05-07 16:57:08 | Biotech ETFs in Focus on String of Q1 Earnings Beats
2019-05-07 08:02:59 | See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
2019-05-02 18:43:44 | Eaton Vance Worldwide Health Sciences Fund Buys 5 New Stocks
2019-05-02 11:18:03 | The Zacks Analyst Blog Highlights: Biogen, Celgene, Incyte, Alexion and Vertex
2019-05-01 11:52:03 | Biotech Stock Roundup: BIIB, VRTX, ALXN Q1 Earnings Top & Other Pipeline Updates
2019-05-01 08:45:12 | Is Alexion ALXN a Solid Growth Stock? 3 Reasons to Think " Yes "
2019-04-30 08:03:39 | See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
2019-04-27 12:56:38 | Top Biotech Stocks for February 2019
2019-04-27 08:40:12 | Edited Transcript of ALXN earnings conference call or presentation 25-Apr-19 12:00pm GMT
2019-04-25 16:05:19 | This Biotech's Newest Drug Could Own The Market In Just 5 Quarters
2019-04-25 15:52:10 | Alexion Pharmaceuticals Inc ALXN Q1 2019 Earnings Call Transcript
2019-04-25 14:00:00 | Alexion Pharmaceuticals Fires on All Cylinders in Q1
2019-04-25 09:31:01 | Alexion ALXN Q1 Earnings Beat Estimates, Guidance Raised